---
figid: PMC5601171__oncotarget-08-60684-g003
figtitle: 'Hedgehog-GLI pathway in embryonic development and cancer: implications
  for pulmonary oncology therapy'
organisms:
- Lareunionomyces loeiensis
- Veratrum californicum
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
- Paraechinus aethiopicus
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
- Danio rerio
pmcid: PMC5601171
filename: oncotarget-08-60684-g003.jpg
figlink: /pmc/articles/PMC5601171/figure/F3/
number: F3
caption: (A) The non-canonical activation of GLI-1/2 through Rack1 kinase has recently
  been described, bypassing pathway activation deficiencies through the binding of
  the SHH ligand to the PTCH receptor. (B) Through the canonic activation mechanism
  of the Hh pathway, diverse strategies have been designed to achieve the selective
  inhibition of the SMO protein. The patented molecules have been employed to generate
  a downstream inhibition of the Hh pathway, through the use of these compounds new
  pre-clinical and clinical trials have been developed, contributing to the survival
  increase of patients diagnosed with diverse epithelial type neoplasms.
papertitle: 'The Hedgehog-GLI pathway in embryonic development and cancer: implications
  for pulmonary oncology therapy.'
reftext: Leonel Armas-LÃ³pez, et al. Oncotarget. 2017 Sep 1;8(36):60684-60703.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9321375
figid_alias: PMC5601171__F3
figtype: Figure
redirect_from: /figures/PMC5601171__F3
ndex: 6fa97e26-df09-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5601171__oncotarget-08-60684-g003.html
  '@type': Dataset
  description: (A) The non-canonical activation of GLI-1/2 through Rack1 kinase has
    recently been described, bypassing pathway activation deficiencies through the
    binding of the SHH ligand to the PTCH receptor. (B) Through the canonic activation
    mechanism of the Hh pathway, diverse strategies have been designed to achieve
    the selective inhibition of the SMO protein. The patented molecules have been
    employed to generate a downstream inhibition of the Hh pathway, through the use
    of these compounds new pre-clinical and clinical trials have been developed, contributing
    to the survival increase of patients diagnosed with diverse epithelial type neoplasms.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SHH
  - NFKB1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - SMO
  - SMOX
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - GLI2
  - CSNK2A1
  - CSNK2A2
  - CSNK2B
  - GLI3
  - PTCH1
  - CCNE1
  - CCNE2
  - CCND1
  - CCND2
  - CCND3
  - FOXM1
  - ABCG2
  - SOX2
  - RACK1
  - SLC25A16
  - GLI1
  - GLA
  - NAT8
  - Shh
  - Nfkb1
  - Pik3r1
  - Smo
  - Smox
  - Mdk
  - Akt1
  - Mtor
  - Gli2
  - Csnk2a1
  - Csnk2a2
  - Gli3
  - Ptch1
  - Foxm1
  - Abcg2
  - Sox2
  - Rack1
  - Slc25a16
  - Gzma
  - Gli1
  - Gla
  - Dif
  - dl
  - Rel
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - smo
  - sm
  - Dsor1
  - Mtk
  - Akt
  - Tor
  - CkIIbeta
  - CkIIbeta2
  - CkIIalpha
  - de
  - CycE
  - CycD
  - wg
  - gl
  - shha
  - mtor
  - gli2a
  - gli3
  - ptch1
  - ptch2
  - foxm1
  - sox2
  - rack1
  - gli1
  - gla
  - AZD8542
  - IPI-926
  - Cancer
---
